Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.
Fleseriu M, Newell-Price J, Pivonello R, Shimatsu A, Auchus RJ, Scaroni C, Belaya Z, Feelders RA, Vila G, Houde G, Walia R, Izquierdo M, Roughton M, Pedroncelli AM, Biller BMK.
Fleseriu M, et al.
Eur J Endocrinol. 2022 Sep 16;187(4):531-541. doi: 10.1530/EJE-22-0317. Print 2022 Oct 1.
Eur J Endocrinol. 2022.
PMID: 35980235
Free PMC article.